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Background & Aims: The expression of gastrin, as a
tumor growth factor, is significantly increased in some
colon cancers compared with the low levels found in
normal mucosa. The aim of this study was to elucidate
the transcriptional mechanisms of gastrin induction in
colon cancer. Methods: Gastrin messenger (mRNA)
levels and K-ras genotype were determined in colon
cancer cell lines and surgical specimens. Colon cancer
cells were transfected with oncogenic ras expression
vectors, and transcriptional activity was assayed with
gastrin-luciferase reporter genes. Results: Colon can-
cer cell lines and tissues with K-ras mutations all had
significantly higher gastrin mRNA levels than those that
were ras wild type. Treatment of several ras mutant cell
lines with PD98059, an inhibitor of mitogen-activated
protein kinase kinase, resulted in a decrease in endog-
enous gastrin mRNA levels. The effects of ras on
gastrin expression appeared to be mediated through
the gastrin promoter because transfection of onco-
genic ras and activated raf expression vectors both
induced gastrin-promoter, luciferase-reporter genes.
The inductive effects of oncogenic ras could be blocked
by the coexpression of dominant negative forms of raf
and extracellular regulated kinase. Conclusions: Onco-
genic ras induces gastrin gene expression through
activation of the Raf-MEK-ERK signal transduction
pathway.
Gastrin, a peptide hormone and trophic factor, haslong been recognized to stimulate mucosal growth
in the upper digestive tract.1,2 More recent findings
suggest that gastrin has proliferative effects in colon
cancer as well. Many studies have shown that exogenously
administered gastrin stimulated the growth and prolifera-
tion of colon cancer cells in culture,3,4 transplanted colon
tumors in mice,5 and carcinogen-induced tumors in rats.6
In addition, antagonism of gastrin effects by antigastrin
antisera,7,8 gastrin receptor antagonists,3,9,10 and anti-
sense gastrin RNA11 inhibited growth of colon cancer
cells in culture and in vivo animal models. There is some
controversy about whether gastrin acts on colon cancer by
hormonal mechanisms through circulating processed
gastrin or through autocrine effects of locally produced,
incompletely processed gastrin.12 Both forms of gastrin
have proliferative effects on colonic mucosa,13 but most
colon tumors that produce gastrin express the incom-
pletely processed, glycine-extended form.14–16
In the normal colon, gastrin expression is greatest
during fetal development and then decreases to a very low
level from birth through maturity.17 Some colon cancers,
but not all, have increased levels of gastrin message
compared with normal mucosa.14,18 Although there is not
much information about what factors induce gastrin
expression, some evidence shows that transforming growth
factor a (TGF-a) and epidermal growth factor (EGF)
stimulate gastrin transcriptional activity in several colon
and pituitary cell lines.19,20 It is well established that
many tumors express autocrine growth factors, but the
signaling cascades initiated and transcriptional mecha-
nisms involved are poorly characterized,21,22 including
those responsible for gastrin induction in colon cancer.
The Ras-Raf signal transduction pathway, which is
frequently involved in oncogenesis, plays a critical role in
regulating genes involved in growth and prolifera-
tion.23–25 Although there is clear evidence that oncogenic
Ras can have transforming effects that are Raf indepen-
dent,26 it is the Ras-Raf-MEK-ERK pathway that re-
sponds to mitogens such as EGF27 and also regulates the
expression of growth factors, such as TGF-a28 and
heparin-binding EGF.29 Such cases suggest that an
autocrine loop can involve Ras signaling and tumor
growth factor expression. To determine if there was a
correlation between oncogenic activation of Ras and
gastrin expression, a panel of human colon cancer cell
Abbreviations used in this paper: EGF, epidermal growth factor;
PCR, polymerase chain reaction; RPA, ribonuclease protection as-
say; SDS, sodium dodecyl sulfate; SSC, standard saline citrate;
TGF-a, transforming growth factor a.
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lines and several tissue specimens were examined for
gastrin expression, ras status, and Ras-Raf pathway
activity.
Materials and Methods
Cell Lines and Tissues
All cell lines were obtained from the American Type
Culture Collection (Manassas, VA). Cells were cultured in the
following media: RPMI 1640 (Colo320HSR and Colo205),
Dulbecco’s modified Eagle medium with high glucose (HT29,
Hct116, Caco-2, and LoVo), and Leibovitz’s L-15 (SW480),
each supplemented with 10% fetal bovine serum (BioWhit-
taker, Walkersville, MD) and 2% penicillin/streptomycin
(10,000 U/mL). Surgical specimens were snap-frozen on resec-
tion and stored at 280°C. Treatment of cells with the MEK
inhibitor PD98059 (Calbiochem, La Jolla, CA) was as follows.
Cells were plated in complete media (plus fetal bovine serum)
at an approximate density of 70% confluency. After 12 hours,
the media were changed to serum-free media with 10 or 100
µmol/L PD98059 (0.5% dimethyl sulfoxide) or diluent alone
(0.5% dimethyl sulfoxide). Cells were harvested 36 hours later
for RNA and protein extraction. Cells appeared to tolerate
PD98059 treatment well such that, at the time of harvest,
there was no significant difference in cell number or morphol-
ogy from the control cells (diluent treatment). Thirty-six hours
of PD98059 treatment was chosen for maximal effect on
gastrin messenger RNA (mRNA) levels because there was no
significant change after 12 hours and moderate change after 24
hours.
Ribonuclease Protection Assay
Riboprobes were generated from antisense templates
from human gastrin exon 2 (nucleotide 304 digested to
nucleotide 210), human gastrin exon 1 and 58-flanking
sequence (nucleotide 109 digested to nucleotide 56), and
human cyclophilin (nucleotide 170 digested to nucleotide
103). Riboprobes were prepared by in vitro transcription
(Riboprobe System; Promega, Madison, WI) incorporating
[a32P]cytidine triphosphate (800 Ci/mmol; Amersham, Arling-
ton Heights, IL). Probes were isolated after urea gel electropho-
resis and extraction (shaking in 300 mmol/L sodium acetate,
0.1 mmol/L EDTA, and 0.2% sodium dodecyl sulfate [SDS] at
50°C for 2 hours). Total RNA preparation was performed by a
standard guanidine isothiocyanate, phenol extraction meth-
od.30 For the ribonuclease protection assay (RPA),31 both
gastrin (1 3 106 cpm) and cyclophilin (1 3 104 cpm) ribo-
probes were combined with 150 µg of total RNA in each
reaction and hybridized for 16 hours at 57°C (1 mmol/L
EDTA; 40 mmol/L piperazine-N,N8-bis(2-ethanesulfonic acid),
pH 6.4; 400 mmol/L NaCl; and 80% formamide). Both
riboprobes were added to each assay to control for RNA
integrity and quantification. After hybridization, samples were
digested with ribonuclease A (20 µg/mL) and ribonuclease T1
(250 U/mL) in 300 mmol/L NaCl, 10 mmol/L Tris (pH 7.4),
and 5 mmol/L EDTA at 37°C for 30 minutes. After the
digestion was stopped, RNA was precipitated and resolved by
denaturing gel electrophoresis. Densitometry was determined
from digitally scanned radiographs, and results were normal-
ized to cyclophilin levels. Because cyclophilin message was so
abundant, approximately 10-fold less cyclophilin probe was
used in Figure 1A.
K-ras Genotyping
Polymerase chain reaction (PCR)-amplified K-ras gene
fragments were prepared from each of the cell lines and tissues.
Analysis of the K-ras genotype at codons 12, 13, and 61 was
accomplished by two methods: slot blot Southern hybridiza-
tion and DNA sequencing of subcloned PCR products.
Genomic DNA was extracted from each sample according to
standard methods31 and digested with EcoR1. PCR was
performed by a standard method incorporating Taq polymerase
(Perkin-Elmer Corp., Norwalk, CT) with 5% formamide added
to the reaction (35 cycles of 80°C for 20 seconds, 48°C for 20
seconds, and 72°C for 30 seconds). Human K-ras primers were
as follows: codon 12-F, 58-ATGACTGAATATAAACTTGT;
codon 12-R, 58-CGTCCACAAAATGATTCTG; codon 61-F,
58-TTCCTACAGGAAGCAAGTAG; and codon 61-R, 58-
CACAAAGAAAGCCCTCCCCA.
Southern Hybridization Analysis
Five hundred nanograms of DNA product from each
reaction was denatured and transferred to Nytran membranes
(Schleicher & Schuell, Keene, NH) for slot blot Southern
hybridization. 32P-labeled oligonucleotide probes encompass-
ing codons 12 and 13, containing mutations in each codon
respectively for glycine (wild type), cysteine, serine, arginine,
valine, aspartate, and alanine, were used for hybridization.
After the blots were pretreated with buffer (53 standard saline
citrate [SSC], 1% SDS, and 0.2% nonfat dried milk),31 probe
was added and incubated at 65°C for 16 hours. Blots were
washed in several changes of 0.23 SSC and 0.1% SDS at 61°C
and autoradiographed. Codon 61 PCR products were not
analyzed by this method.
DNA Sequence Analysis
PCR products were purified by agarose gel electropho-
resis and subcloned into pGEM-T vector (Promega) by stan-
dard methods. For each sample, dideoxy sequencing confirmed
the genotype identified in the slot blot assays. Codon 61 PCR
products from ColoHSR, Colo205, HT29, and Caco-2 were
subcloned and sequenced.
Statistical Analysis
Statistical analysis of gastrin RPA and ras status used a
Mann–Whitney test for the central tendency of two distributions.
ERK Assay
ERK activity was determined by an in vitro immune
complex kinase assay32 with recombinant GST-Elk as the
substrate.33 Protein A sepharose and anti-ERK2 antisera (C14;
Santa Cruz Biotechnology, Santa Cruz, CA), which can also
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cross-react with ERK1, were used to immunoprecipitate ERKs
from equivalent amounts of whole-cell extracts. After washing
the immune complexes, [g-32P]adenosine triphosphate and
recombinant GST-Elk were then added for the kinase reaction.
The reaction products were resolved by 10% SDS gel electro-
phoresis and were autoradiographed.
Western Blot Analysis
ERK1,2 and phosphorylated ERK1,2 levels were deter-
mined by Western blot analysis. Equivalent amounts of protein
(100 µg) from whole-cell extracts were resolved by 10%
SDS–polyacrylamide gel electrophoresis (PAGE) and electro-
transferred to polyvinylidene difluoride membranes (Tropi-
fluor; Tropix, Bedford, MA). After blocking nonspecific bind-
ing (I-block; Tropix), blots were probed with anti-ERK2 (C14;
Santa Cruz) or antiphosphorylated ERK1,2 (Anti-Active MAPK
pAb; Promega) antisera. Both antisera are cross-reactive with
p44 ERK1 and p42 ERK2. After probing with the primary
antisera, blots were washed and probed with anti-rabbit
antisera conjugated with alkaline phosphatase. The blots were
developed with CDP-Star chemiluminescent reagent (Tropix).
It should be noted that p44 ERK1 was not electrophoreti-
cally resolved from p42 ERK2. Hence, ERK1,2 migrated as a
single complex. Adjusting the electrophoretic conditions in
subsequent confirmatory experiments did achieve resolution of
two bands, which when probed with the Anti-Active MAPK
antisera showed that both had equivalent degrees of phosphor-
ylation (data not shown).
Transfection and Transcriptional Analysis
Colo HSR cells were plated in six-well plates (Falcon;
Becton Dickinson, Lincoln Park, NJ) at approximately 70%
confluency in complete media (RPMI 1640 1 10% fetal
bovine serum and 2% penicillin/streptomycin). Cells were
transfected 12 hours later by a standard CaPO4 technique,31 and
the media were changed to RPMI 1640 supplemented with
0.5% fetal bovine serum. Cells were harvested at 48 hours for
luciferase34 and protein35 assays. Typically, 1 µg of reporter
plasmid and 0.25–0.5 µg of expression plasmid were trans-
fected in each 35-mm well. Construction of gastrin promoter
plasmids, 200 GasLuc and 1300 GasLuc, which denote the
length of 58-flanking sequence, has been reported previously.36
The luciferase reporter plasmids p(Py)2 Luc,37 pGL Col3 Luc,38
and pT81 Luc39 have been described previously. Expression
plasmids, including pZip H-ras61L and pZip neo,40 pZip
rafCAAX,26 pZip Rac17N, and pZip Rho19N,41 pVL raf301,42 and
pCMV ERK1,2KM,43 have been described previously. Internal
transfection standards were not used, but rather luciferase assays
were checked for equivalent protein concentrations. Data were
derived from the mean of triplicate transfected wells, and
transfection experiments were repeated three to four times each.
Results
Gastrin mRNA Levels in Colon Cancer
A sensitive RPA was developed for the detection
and quantification of gastrin mRNA levels in colon
A
C
Figure 1. (A) RPA of colon cancer cells treated with the MEK inhibitor
PD98059. Hct116, LoVo, and SW480 cells were treated for 36 hours
with or without inhibitor and subjected to RPA as described in
Materials and Methods. Digested gastrin and cyclophilin riboprobes
are indicated by the arrows. The undigested probes are shown in lane
1, and the positive control for gastrin message is shown in lane 2.
(B) Relative gastrin mRNA levels in cells treated with or without
PD98059. Densitometry of gastrin and cyclophilin mRNA levels from
RPA (A) with results normalized to cyclophilin message levels. (C)
Western blot of phosphorylated and total ERK1,2 from colon cancer
cells treated with the MEK inhibitor PD98059. Protein extracts (100
µg each) from cells treated for 36 hours with PD98059 or diluent were
resolved by 10% SDS-PAGE and blotted as described in Materials and
Methods. Lane numbers refer to the same lanes in A. Western blot
with antisera and chemiluminescent detection was as described in
Materials and Methods.
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cancer cell lines and tissue samples obtained from surgical
resection. Antisense riboprobes derived from human
gastrin (exon 2) and cyclophilin gene templates were used
in each assay. Cyclophilin mRNA, transcribed from a
ubiquitous housekeeping gene, served as an internal
control for mRNA integrity and reaction conditions.
Total RNA samples from seven colon cancer cell lines and
two pairs of human tissue samples were used for the RPA
shown in Figure 2A. Undigested gastrin and cyclophilin
riboprobes are present in lane 17. Lanes 1 and 2 contain
reactions from a positive gastrin message control and a
negative control (transfer RNA only), respectively. Gas-
trin mRNA was readily detectable in total RNA prepared
from SW480, HT29, Hct116, and LoVo cells but was
barely discernible in Colo205, ColoHSR, and Caco-2
cells.
Tissue specimens from two colon cancers and their
paired normal margins were assayed by gastrin and
cyclophilin RPA. Tumor 1 (T1) had significantly elevated
gastrin mRNA levels compared with its normal margin
tissue (N1). Tumor 2 (T2) had undetectable gastrin
message, as did its normal margin (N2). Additional tissue
specimens from 9 other colon cancers were assayed by
gastrin and cyclophilin RPA as shown in Figure 2B.
Gastrin mRNA levels were elevated in tumors T3, T4,
T6, T8, and T11. Relative amounts of gastrin and
cyclophilin mRNAs were determined from both RPAs by
densitometry. The cyclophilin mRNA levels were normal-
A B
Figure 2. (A) RPA for gastrin and cyclophilin message. Total RNA (150 µg each reaction) was hybridized with gastrin and cyclophilin riboprobes and
digested as described in Materials and Methods. Digested products are indicated with the arrows. Samples were as follows: lanes 3 and 14,
LoVo; lane 4, Hct116; lane 5, Caco-2; lane 6, ColoHSR; lane 7, Colo205; lane 8, HT29; lane 9, SW480; lane 10, tumor 2; lane 11, margin 2; lane
12, tumor 1; lane 13, margin 1; lanes 2 and 15, transfer RNA tRNA; lanes 1 and 16, human gastrin mouse transgene; and lane 17, undigested
probes. (B) RPA for gastrin and cyclophilin message in colon cancer specimens. Total RNA (150 µg each reaction) was hybridized with gastrin and
cyclophilin riboprobes and digested as described in Materials and Methods. Digested products are indicated with the arrows. Samples were as
follows: lane 18, transfer RNA; lane 19, human gastrin mouse transgene; lane 20, tumor 3; lane 21, T4; lane 22, T5; lane 24, T6; lane 25, T7; lane
26, T8; lane 27, T9; lane 28, T10; and lane 29, T11. Of note, lane 18 (transfer RNA control) had a gel artifact of smeared signal from the adjacent
lane, and the sample in lane 23 had degraded RNA. (C) Gastrin mRNA levels relative to normalized cyclophilin mRNA. Densitometry of RPA (A) with
results normalized to cyclophilin message levels. A was scanned, and densities were determined for gastrin message levels. A shorter exposure
of the radiograph for A was used to determine cyclophilin signal densities. K-ras genotypes for each sample are listed (see Table 1). WT, wild type.
(D) Gastrin mRNA levels relative to normalized cyclophilin mRNA of colon cancer specimens. Densitometry of RPA (B) with results normalized to
cyclophilin message levels. K-ras genotypes for each sample are listed (see Table 1).
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ized across the samples, and gastrin-relative-to-cy-
clophilin levels were determined for each sample and
plotted as shown in Figure 2C and D. A .20-fold range
in relative gastrin expression was observed between the
low-expressing ColoHSR cells and the high-expressing
SW480 cells. The results from the surgical samples
indicate that, although gastrin expression is typically
very low in normal adult colon tissue, it can be signifi-
cantly elevated in some but not all colon tumors.
Determination of the transcriptional start site was
done by hybridization of RNA from several colon cancer
cell lines with a riboprobe prepared from a template of
human gastrin exon 1 and additional 58-flanking se-
quence. This RPA yielded protected fragments identical
in length to those obtained from human gastric antral
RNA (data not shown), confirming that gastrin mRNA
expression in colon cancer occurs from the same transcrip-
tional start site as has been described in other tissues.44,45
K-ras Genotypes
K-ras genotypes were determined from PCR-
amplified DNA of each of the cell lines and tissue
samples. Mutations in K-ras codons 12, 13, and 61 were
detected by a combination of allele-specific hybridization
and sequencing cloned PCR-amplified regions of the
K-ras gene. Results of ras genotyping are shown in Table
1. Tumors T1, T3, T4, T6, T8, and T11, as well as
SW480, HT29, LoVo, and Hct116 cell lines were found
to have oncogenic K-ras mutations. In contrast, Colo205,
Caco-2, and ColoHSR cells; tumors T2, T5, T7, T9, and
T10; and both normal colon margin tissues were wild
type. Of note, HT29 cells and tumor T11 were found to
have an oncogenic mutation in codon 61 (Gln . Leu),
which is unusual for K-ras. Previous reports of HT29
having wild-type K-ras were based on sequencing just the
codon 12/13 region.46,47 All samples with ras mutations
were heterozygous with a normal allele, with the excep-
tion of SW480 which had homozygous ras mutations and
no detectable normal allele. In each case, the sequence
data confirmed the results from the allele-specific oligo-
nucleotide hybridization blots. Comparison of the results
from the gastrin RPA and ras genotyping shows that the
samples possessing ras mutations also have the highest
gastrin mRNA levels with no overlap between the two
groups (P 5 0.002). Interestingly, of the cell lines with
oncogenic ras mutations, the only one that was homozy-
gous, SW480, had the highest expression of gastrin.
These findings suggest a direct correlation between
oncogenic activation of ras and induction of gastrin gene
expression.
ERK Activity and Phosphorylation
ERK activity was assessed to determine if the cell
lines and tissues with oncogenic ras mutations have an
activated Ras-Raf signal transduction pathway. ERK,
which was immunoprecipitated from the cell extracts,
was incubated with recombinant GST-Elk protein, a
substrate for the kinase enzyme. Phosphorylated GST-Elk
was electrophoretically resolved, and the results of the
assay are shown in Figure 3A. Densitometry of the
GST-Elk complex is shown in Figure 3B. With the
exception of Colo205 (lane 6), ras mutant cell lines had
greater ERK activity than the wild-type cell lines
ColoHSR and Caco-2. Among the tissue samples, only
the ras mutant tumor 1 (T1) had significantly elevated
ERK activity, whereas the other ras wild-type tumor
sample (T2) was comparable to the normal margin tissue.
It is notable that all of the samples appeared to have
equivalent amounts of total ERK1,2, as determined by
Western blot (Figure 3C). These assays suggest that,
although total ERK1,2 levels are fairly constant, in-
creased ERK activity tends to occur in those tissues with
oncogenic ras mutations.
MEK Inhibition and Endogenous Gastrin
mRNA Levels
If activation of the Ras-Raf signal transduction
pathway is in part responsible for induction of gastrin
gene expression, inhibition of the ras pathway would
likely result in decreased levels of gastrin message. A
specific MEK inhibitor, PD98059,48 was used to treat
several colon cancer cell lines, from which total RNA was
extracted and assayed for gastrin and cyclophilin message
levels. SW480, LoVo, and Hct116 cells, all of which have
Table 1. K-ras Genotypes of Colon Cancer Cell Lines and
Surgical Tissue Samples: Confirmation of Southern
Oligonucleotide Hybridization by DNA Sequencing
Sample Codon (mutation) Genotype
Hct116 13 (GAC) 13Asp
LoVo 13 (GAC) 13Asp
HT29 61 (CTA) 61Leu
SW480 12 (GTT) 12Val homozygous
T1 12 (CGT) 12Arg
T3 12 (GTT) 12Val
T4 12 (GTT) 12Val
T6 12 (GTT) 12Val
T8 13 (GAC) 13Asp
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oncogenic ras mutations, were treated with 0, 10, and
100 µmol/L PD98059. As shown in the RPA (Figure
1A), gastrin message levels were significantly lower in
treated cells than those controls that were administered
vehicle only. There was no significant variation in the
cyclophilin message levels. The cyclophilin mRNA levels
were normalized across the samples, and gastrin-relative-
to-cyclophilin levels were determined for each sample
and plotted as shown in Figure 1B. These results show
that, when controlled for cyclophilin signal intensity,
relative gastrin message levels were approximately 60%
lower with MEK inhibition. It is noteworthy that gastrin
expression in similarly treated ColoHSR cells did not
decrease, indicating that the PD98059 had no significant
effect on the low basal activity of the Ras-Raf pathway
(data not shown).
An indirect measure of kinase activity can be ascer-
tained by probing a Western blot with antisera specific
for the phosphorylated forms of ERK. Protein extracts
from SW480, LoVo, and Hct116 cells were resolved and
blotted by antisera specific for phosphorylated, active
ERK1,2 and total ERK1,2 (Figure 1C). As shown in
Figure 1C, Western blot analysis confirmed that PD98059
treatment led to a decrease in activated ERKs without
changing the overall ERK protein levels. These results
support the conclusion that, in cells with oncogenic ras
mutations, interference with the Raf-MEK-ERK path-
way will down-regulate gastrin mRNA levels, yet not
affect levels of the housekeeping gene cyclophilin.
Oncogenic ras Activates Gastrin-Promoter,
Luciferase-Reporter Genes
Transient transfection experiments with ColoHSR
cells, which are ras wild type and have low endogenous
gastrin expression, were performed to directly examine
the transcriptional effects of oncogenic ras on the gastrin
gene promoter (Figure 4). ColoHSR cells were cotrans-
fected with neomycin or oncogenic ras expression vectors
and a gastrin-promoter, luciferase-reporter gene contain-
ing 200 or 1300 base pairs of gastrin 58-flanking
sequence. Transfection of an H-ras61Leu expression vector
stimulated expression of cotransfected gastrin-promoter,
luciferase-reporter genes 6–8-fold compared with cells
expressing the control neomycin vector. Both lengths of
the gastrin promoter seemed to be equally activated,
A
C
Figure 3. (A) ERK kinase activity of colon cancer cells and tissues.
Whole-cell and tissue extracts (25 µg protein each) from the same
samples shown in Figure 2A were used in a kinase assay as described
in Materials and Methods. The phosphorylated substrate GST-Elk was
electrophoresed, and the autoradiogram was obtained. (B) Levels of
phosphorylated GST-Elk. Densitometry of ERK kinase assay shown in
A. (C) Levels of ERK1,2 in colon cancer cells and tissues. Western blot
of total ERK1,2 from colon cancer cell lines and tissue samples.
Whole-cell protein extracts (100 µg each) were resolved by 10%
SDS-PAGE, electrotransferred, and probed with anti-ERK2 as de-
scribed in Materials and Methods. Numbering of lanes corresponds to
those in A.
Figure 4. Oncogenic ras activation of gastrin-luciferase transcription
in ColoHSR cells. Cells were transfected with pZip H-ras61L (S) or pZip
neomycin (M) expression vectors (0.25 µg/well) and a reporter
plasmid (1 µg) by a CaPO4 transient transfection method as noted. A
polyoma viral promoter vector p(Py)2Luc, with tandem ras responsive
elements served as a positive control, whereas the minimal thymidine
kinase promoter vector pT81Luc served as a negative control. A
collagen gene promoter vector, pGLCol3Luc, containing 220 base
pairs of 58-flanking sequence, was included for comparison purposes.
Luciferase activity was determined at 48 hours. Each data point
represents the mean of triplicate determinations (6SEM). RLU,
relative light units.
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suggesting that the Ras-responsive cis-regulatory ele-
ments are within the proximal 200 bases of the gastrin
58-flanking sequence. A polyoma viral promoter vector,
p(Py)2Luc, with tandem Ras-responsive elements had
approximately 8-fold induction. A collagen gene pro-
moter vector, pGLCol3Luc, had 2-fold induction, whereas
the minimal thymidine kinase promoter vector pT81Luc
was not induced. These results suggest that oncogenic ras
can stimulate gastrin transcriptional activity in a gene-
specific manner. It is noteworthy that similar results were
obtained with transfection of the oncogenic K-ras12Val
vector (data not shown), indicating that both forms of
oncogenic ras can induce gastrin.
Because oncogenic Ras can act along several kinase
pathways,49 the effect of activated Raf on gastrin-
luciferase expression was examined next. As shown in
Figure 5, transfection of ColoHSR cells with an expres-
sion vector for a constitutively active form of Raf, pZIP
rafCAAX, resulted in 7–10-fold stimulation of gastrin-
luciferase expression. Again, the positive control p(Py)2Luc
was stimulated, but the collagen and thymidine kinase
promoter vectors were not. These results suggest that Ras
stimulation of gastrin transcriptional activity is mediated
through the Raf-MEK-ERK pathway.
To confirm the specificity of ras stimulation of gastrin
promoter activity, ColoHSR cells were cotransfected with
pZip vectors expressing H-ras61Leu, dominant negative
kinases, and the 200 gastrin-luciferase reporter gene. The
effects on gastrin-luciferase expression by the cotrans-
fected expression vectors are shown in Figure 6. Coexpres-
sion of H-ras61Leu with either dominant negative vectors
for raf or ERK1,2 resulted in substantial inhibition of the
ras effect on gastrin-luciferase expression. Dominant
negative vectors for rho and rac, which are collateral
ras-associated pathways, had no effect on ras stimulation
of gastrin-luciferase expression. These results and those in
the previous figure are consistent with the following: the
transcriptional activation of gastrin by oncogenic Ras is
mediated principally through the Raf-MEK-ERK signal-
ing pathway.
Because oncogenic Ras apparently increases Raf-MEK-
ERK pathway activity and drives gastrin transcription,
then one would predict that inhibition of ERKs would
have a greater effect on ras-transformed cells than those
that are ras wild type. To test this hypothesis, plasmids
for dominant negative ERK kinases or the negative
control neomycin were cotransfected with gastrin-
luciferase reporter genes into ras mutant cell lines LoVo
and Hct116 and a ras wild-type cell line ColoHSR.
Unlike the experiment shown in Figure 6, an oncogenic
ras expression vector was not cotransfected. As shown in
Figure 7, both the ras mutant cell lines experienced a
.60% decrease in gastrin-luciferase transcriptional activ-
ity with the presence of dominant negative ERKs.
However, the ras wild-type cell line was not significantly
affected by the dominant negative ERKs. These results
were corroborated by treating Hct116, LoVo, and
ColoHSR cells with PD98059 and assaying the resultant
gastrin-luciferase transcriptional activity (data not shown).
Gastrin-luciferase activity decreased 50% in the ras
mutant cells but was not affected in the ras wild-type
ColoHSR. Such findings showing that specific inhibitors
of the Ras-Raf pathway down-regulate gastrin-luciferase
activity support the conclusion that oncogenic Ras
induces gastrin gene expression through transcriptional
activation of the gastrin promoter.
Figure 6. raf(301) and ERK1,2(KM) dominant negative kinases par-
tially block H-ras61L activation of gastrin-luciferase transcription in
ColoHSR cells. Cells were cotransfected with pZip H-ras61L or pZip
neomycin (0.25 µg/well), a dominant negative kinase expression
vector (0.5 µg/well), and the 200 Gas Luc reporter plasmid (1
µg/well). Cells were harvested at 48 hours for luciferase assays, and
results of triplicate determinations are shown (6 SEM). RLU, relative
light units.
Figure 5. raf CAAX activates gastrin-luciferase transcription in ColoHSR
cells. Cells were transfected with pZip rafCAAX (S) or pZip neomycin
(M) expression vectors (0.5 µg/well) and a reporter plasmid (1
µg/well) as described in Materials and Methods. After 48 hours, cells
were harvested for luciferase assays, and results of triplicate determi-
nations are shown (6SEM). RLU, relative light units.
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Discussion
Several studies have noted that colon cancer
tumors often have increased levels of gastrin peptides,
particularly incompletely processed forms.14,15,18 Normal
gastrin expression in the colon appears to be much higher
during fetal development than after maturity.17 Hence,
the elevated expression of gastrin in colon cancer likely
occurs through oncofetal transcriptional mechanisms,
which to date have not been well characterized. The
results of this study establish that oncogenic activation of
the Ras signal transduction pathway induces gastrin gene
expression. This evidence is based on the following: (1) a
close correlation between the presence of oncogenic K-ras
mutations and increased gastrin message levels, (2) the
down-regulation of endogenous gastrin message levels in
cells treated with a specific MEK inhibitor, (3) the
stimulation of gastrin transcriptional activity by acti-
vated oncogenic ras or raf, and (4) the ability of specific
inhibitors of the Ras-Raf pathway to interfere with
gastrin transcriptional activation. This is the first evi-
dence that gastrin is a ras-responsive gene and that Ras is
acting on the gastrin promoter through a Raf-MEK-ERK
pathway.
Oncogenic ras is known to induce the expression of
other growth factors, such as heparin-binding EGF,29
vascular endothelial growth factor,50 and TGF-a.28 Hepa-
rin-binding EGF appears to be an early-response gene
responding to Raf induction within several hours.29 The
transcriptional mechanism of Ras-Raf induction of hepa-
rin-binding EGF expression involves ERK phosphoryla-
tion of an Ets-2 transcription factor and its binding to a
composite AP-1/Ets site in the heparin-binding EGF
promoter.51 In contrast, the gastrin gene promoter does
not appear to have consensus motifs for AP-1 response
elements (Boel et al.52 and unpublished observations,
December, 1997). Of course, it is possible that AP-1 or
Ets transcription factors are acting through nonconsensus
binding sites.53 Likewise, a study by Marks et al.
indicates that EGF stimulation of gastrin transcriptional
activity in pituitary cells depends in part on c-fos
expression, suggesting a role for AP-1.54 In addition, they
have discovered that in gastric and pituitary cell lines,
EGF stimulation of gastrin transcription is mediated
through a novel GC-rich proximal cis-regulatory gastrin
EGF response element.55 Because the 200–base pair
gastrin-luciferase reporter gene is ras responsive (Figure
5), it is likely that the ras-response elements are located in
the proximal gastrin promoter and may include gastrin
EGF response element, as well as other known elements.
Further studies are indicated to identify ras-responsive
elements of the gastrin promoter and to determine the
transcriptional mechanism of induction.
It is also possible that ras induction of gastrin is
mediated indirectly through other cytokines or growth
factors. For example, ras could induce TGF-a expression,
which in turn stimulates gastrin expression through an
autocrine mechanism. Several studies have shown that ras
induction of TGF-a expression in rat intestinal epithelial
cells leads to an autocrine loop of TGF-a growth
stimulation.28,56 Howell et al. have linked gastrin and
TGF-a by showing that gastrin message levels in Hct116
cells fluctuate according to autocrine TGF-a stimula-
tion.20 They found that when the TGF-a autocrine loop
was interrupted by expression of an antisense TGF-a
message, gastrin mRNA levels decreased. However, when
Baldwin and Zhang analyzed gastrin and TGF-a mRNA
levels in seven colon cancer cell lines, they did not find a
close correlation between the two factors.57 Hence, it is
possible that stimulation of gastrin gene expression
occurs as a secondary event in response to ras induction of
another growth factor in addition to TGF-a.
We found that, although total ERK levels were
equivalent among all the cell lines tested, increased ERK
activity generally correlated with the presence of onco-
genic ras mutations (see Figure 3). However, this associa-
tion between ERK activity and ras status was not as
strong as that of oncogenic ras and gastrin induction.
Nonetheless, these results are consistent with oncogenic
ras causing constitutive activation of the Raf-MEK-ERK
pathway.33,58 However, Licato et al. recently reported
that, although ERK and Jun kinase activities were
increased in colon tumors of mice treated with dimethyl-
hydrazine, there was no direct correlation between the
ERK activity and ras status of the tumor.59 Although one
might expect that ERK activity should always correlate
Figure 7. ERK1,2 (KM) dominant negative kinases cause a decrease
in gastrin-luciferase transcriptional activity in ras mutant cells but not
in ras wild-type cells. Cells were cotransfected with the 1300 gastrin-
luciferase reporter plasmids (1 µg/well) and expression vectors (0.5
µg/well) for dominant negative ERK1,2 (S) or neomycin (M) as
described in Materials and Methods. Cells were harvested at 48 hours
for luciferase assays, and results of triplicate determinations are
shown (6 SEM).
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with ras status, it is likely to be more complicated in that
other kinases and phosphatases affect the Raf-MEK-ERK
pathway.60–62 Thus, overall ERK activity may be modu-
lated by multiple signal pathways and not limited to the
state of Ras activation. It will be important to systemati-
cally study larger numbers of tumor samples to determine
the degree of correlation between ERK activities and ras
status.
Several studies have noted that gastrin expression is
not uniformly increased in colon cancer tumors.18,57 A
study by Finley et al. noted that, of the colon tumors
assayed, more than half of the tumor cells stained for
gastrin and 2 of 4 tumors had detectable gastrin mRNA.18
The results of the current study indicate that gastrin
expression is indeed variable but dependent on oncogenic
ras stimulation. This correlation fits the observations that
oncogenic K-ras mutations occur in about 50% of the
colon tumors.63 Some studies indicate that tumors with
oncogenic K-ras mutations are more aggressive and
associated with a shorter mean survival time.64,65 As
Singh et al. and Wang et al. have shown, induction of
gastrin expression would give the tumors a significant
growth advantage.11,13 Although it remains to be deter-
mined whether all colon tumors with oncogenic K-ras
mutations have increased gastrin expression, it is likely
that assessment of both ras status and relative gastrin
expression will provide useful prognostic information.
Such information may be critical for determining which
patients with colon cancer will benefit from antigastrin
therapy.11
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